![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
U.S. index futures are virtually flat in pre-market trading this Wednesday, with Wall Street awaiting April’s consumer price index data. At 7:18 AM, Dow Jones futures (DOWI:DJI) were up 3...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 1.40845070423 | 1.42 | 1.47 | 1.37 | 48105 | 1.3934167 | CS |
4 | 0.17 | 13.3858267717 | 1.27 | 1.53 | 1.27 | 101153 | 1.39336608 | CS |
12 | -0.19 | -11.6564417178 | 1.63 | 1.72 | 1.25 | 139759 | 1.44077877 | CS |
26 | -0.11 | -7.09677419355 | 1.55 | 1.89 | 1.25 | 233696 | 1.59062219 | CS |
52 | 0.04 | 2.85714285714 | 1.4 | 1.89 | 0.99 | 240739 | 1.46679672 | CS |
156 | -12.89 | -89.9511514306 | 14.33 | 19.87 | 0.6801 | 960838 | 2.17441462 | CS |
260 | -8.69 | -85.7847976308 | 10.13 | 23.639 | 0.6801 | 646446 | 3.49270417 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions